Caliway Biopharmaceuticals Co. L
6919
Classificação em ações
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Preço da ação
$2.29
Valor de mercado
$3.56B
Variação (1 dia)
-2.50%
Variação (1 ano)
-57.22%
País
TW
Negociar Caliway Biopharmaceuticals Co. L (6919)
Categoria
Healthcare
Histórico de rendimento de dividendos para Caliway Biopharmaceuticals Co. L (6919)
O rendimento de dividendos (TTM) da Caliway Biopharmaceuticals Co. L (símbolo da ação: 6919) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Caliway Biopharmaceuticals Co. L (6919) de 2025 a 2026
Rendimento de dividendos no final de cada ano (TTM)
| Ano | Rendimento de Dividendos | Alterar |
|---|---|---|
| 2025 | 0.00% | 0.00% |
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
| Empresa | Rendimento de Dividendos | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
